Showing results (101-110 of 153) with videos related to
Sort By:
Pageof 16
Cancers|November 27, 2025
Results of the First Folate Receptor Alpha Testing Trial by the German Quality Assurance Initiative in Pathology (QuIP®)Alexander Scheiter, Sven Mattern, Verena Gassenmaier, et al.Cancer Research|June 5, 2013
Loss of p120-catenin induces metastatic progression of breast cancer by inducing anoikis resistance and augmenting growth factor receptor signalingRon C J Schackmann, Sjoerd Klarenbeek, Eva J Vlug, et al.Frontiers in Endocrinology|August 15, 2022
Small molecules to regulate the GH/IGF1 axis by inhibiting the growth hormone receptor synthesisLieke M van der Velden, Peter Maas, Miranda van Amersfoort, et al.Nature Communications|July 16, 2019
Corrigendum: p120-catenin prevents multinucleation through control of MKLP1-dependent RhoA activity during cytokinesisRobert A H van de Ven, Jolien S de Groot, Danielle Park, et al.Nature Communications|December 23, 2016
p120-catenin prevents multinucleation through control of MKLP1-dependent RhoA activity during cytokinesisRobert A H van de Ven, Jolien S de Groot, Danielle Park, et al.Proceedings of the National Academy of Sciences of the United States of America|October 31, 2008
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsSven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, et al.Laboratory Investigation; a Journal of Technical Methods and Pathology|March 6, 2025
Clinicopathological Characteristics of a Distinct Tumor Phenotype: Invasive Lobular Carcinoma With Tubular Elements in the West German Study Group ADAPTcycle TrialMartin Radner, Sandy Burmeister, Katarzyna Jóźwiak, et al.Laboratory Investigation; a Journal of Technical Methods and Pathology|October 17, 2017
Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2βMieke Raap, Malte Gronewold, Henriette Christgen, et al.Breast (Edinburgh, Scotland)|June 24, 2021
The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrialsMonika Graeser, Nadia Harbeck, Oleg Gluz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2026
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerOleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.Pageof 16